Access Pharmaceuticals (Access) has entered into an agreement with a commercial manufacturer, Accupac, to produce its FDA-approved MuGard for North American distribution.
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth.
The company plans to use the initial batches of MuGard in connection with one or more market seeding studies to be conducted in the US, pursuant to protocols that are currently being developed. Access hopes to finalize these protocols and begin one or more market seeding studies in Q4 2009.
Jeffrey Davis, president and CEO of Access, said: “Access is moving forward with the development of MuGard in North America. Establishing our relationship with Accupac is critical to our successful commercialisation of MuGard. In addition, Access is currently evaluating potential eMarketing partners as well as potential co-promotion or other licensing opportunities.”